SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of competing RRP treatment Voceryq has put Precigens PAPZIMEOS in focus, with traders debating whether the new entrant will erode its sales. Bears see a direct competitive threat, while bulls point to PAPZIMEOS full approval and commercial head start and question Inovios ability to commercialize an accelerated-approval drug.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Discussion centers on Compounds institutional-market launch and treasury-backed institutional finance push, which traders view as a potential catalyst alongside the protocols planned upgrades. Optimism about COMPs limited supply and a possible breakout is tempered by complaints that it continues to lag other crypto assets.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 report and stronger-than-expected Q4 profit outlook are driving attention, with shares rising despite revenue and EPS misses. Traders are focused on subscriber growth and improved margins, while some question the rally given the earnings shortfall and higher expenses.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios shares sold off despite a quarterly earnings beat as its outlook signaled slower organic growth, prompting concerns about deceleration and softer guidance. Traders are split between viewing the drop as an overreaction and buy-the-dip opportunity, and seeing the slower outlook as outweighing the results; some remain positive on Twilios longer-term AI communications potential.

iShares Trust - iShares China Large-Cap ETF

iShares China Large-Cap ETF

FXI is drawing attention amid a broad selloff in Chinese equities, with traders citing the CSI 300s bear-market decline, weak domestic demand and added uncertainty around AI export restrictions. The community is divided between warnings of a prolonged downturn and views that beaten-down China shares may be nearing a base.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Attention is centered on Zebecs payroll and payments integrations, particularly the MoneyGram/Stellar connection and a reported Germany/AllUnity deployment, which bullish traders view as adoption catalysts. Skeptics counter that partnership news has yet to translate into sustained token demand or price strength, while speculation about additional Robinhood or Ripple links remains unconfirmed.

OpenAI

OpenAIs potential IPO is driving attention, with traders debating reports that the listing could slip to 2027 amid market volatility and heightened safety and legal scrutiny. The discussion is split between enthusiasm for a major AI listing and skepticism about OpenAIs valuation, cash burn, and ability to sustain growth against competitors.

Artificial Superintelligence Alliance (FET) is a cryptocurrency launched in 2018. Artificial Superintelligence Alliance has a current supply of 2,714,384,546.672 with 2,419,135,848.3909366 in circulation. The last known price of Artificial Superintelligence Alliance is 0.16707757 USD and is up 1.84 over the last 24 hours. It is currently trading on 592 active market(s) with $193,186,396.23 traded over the last 24 hours. More information can be found at https://superintelligence.io/.

Fetch.ai

FETs price action and its place in the AI-crypto trade dominate the discussion, with traders watching for a breakout and describing relative strength during broader market weakness. Bullish dip-buying and accumulation hopes coexist with frustration over lagging performance and concern that Bitcoin weakness could weigh on the token.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of whether the S&P 500 rally is broadening beyond mega-cap tech, with traders highlighting its relative strength and recent highs as evidence of rotation into the average stock. Others warn that participation remains uneven and question whether the rotation can persist, especially as technology leadership shifts.

Crocs, Inc. engages in the design, development, manufacture, worldwide marketing, sale, and distribution of lifestyle footwear and accessories. It operates through the Crocs Brand and HEYDUDE Brand segments. The Crocs Brand segment refers to the United States, South Korea, China, Japan, Singapore, Canada, Germany, Great Britain, France, Malaysia, Australia, Puerto Rico, the Netherlands, Australia, India, and Ireland. The HEYDUDE Brand segment focuses on the United States. The company was founded by Scott Seamans, George B. Boedecker, Jr., and Lyndon V. Hanson III in 2002 and is headquartered in Broomfield, CO.

Crocs Inc

Crocs is drawing attention after quarterly results topped expectations and management raised its outlook, citing a continuing HEYDUDE recovery and steady demand for its core brand; the news fueled a sharp rally. Traders are cheering the breakout, while others warn of profit-taking and point to continued weakness in North American sales.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Vanguard Russell 2000 Growth Index Fund ETF Shares (VTWG) Be on Your Investing Radar?

ABUS Stock Surges 10% Today — What’s Driving This Super Rally?

Equity

Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.


APPS Stock Headed For Best Single-Day Gains In Nearly 14 Months — Q1 Beat Has Wall Street Believing That The Growth Is Just Beginning

Shares of Digital Turbine hit a 52-week high on Wednesday after the company reported its first-quarter results earlier in the day.

This Critical Materials Stock Surged Over 150% In A Year – The Firm’s Now Ready To Hit 2026 Production Guidance In Just 6 Months

Energy Fuels expects to produce 1.6 million pounds of finished uranium from January through June 2026 at its 100%-owned White Mesa Mill in Utah.


APPS Stock Soars 53%, On Track For Best Single-Day Gains In 11 Months — Why Did BofA Turn Bullish On Digital Turbine?

Digital Turbine reported earnings per share of $0.16 in Q4 on revenue of $143 million, while Wall Street expected an EPS of $0.09 on revenue of $133 million.

WYFI Stock Tumbles Nearly 10% After Q4 Earnings Miss — What's Wall Street's Take?

Craig-Hallum lowered its price target on the company to $21 from $25, while maintaining a ‘Buy’ rating on the stock, according to Investing.com. 

ATOM Stock Is Falling Today After Atomera Announces Stock Offering At A Deep Discount

The company announced on Monday that it has entered into a definitive agreement to sell 5 million shares of its common stock at an offering price of $5 per share.

Vanguard Scottsdale Funds - Vanguard Russell 2000 Growth Index ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The company said it will fund the repurchase with cash in hand.</li><li>The offer will likely commence on or about Aug. 24, 2026, and is expected to expire on or about Sept. 29, 2026.</li><li>During the second quarter, Arbutus Biopharma reported revenue of $1.01 million compared to an estimated $0.68 million as per Fiscal.ai data.</li></ul>Shares of Arbutus Biopharma Corporation (ABUS) surged over 10% in pre-market trading on Friday after the firm announced its intent to repurchase up to $230 million of its common shares.Arbutus Biopharma said it will repurchase the common shares at a purchase price of not less than $5 per share and not more than $5.75 per share, in cash, less any applicable withholding taxes and without interest.The company said it will fund the repurchase with cash in hand. The offer will likely commence on or about Aug. 24, 2026, and is expected to expire on or about Sept. 29, 2026.If Friday’s pre-market level holds, the stock will hit its July highs.<h2 class="st-heading-2">International Lawsuits</h2>Last month, the company, along with its exclusive licensee, Genevant Sciences GmbH, a subsidiary of Roivant Sciences (ROIV), announced the filing of three international lawsuits seeking to enforce patents protecting their innovative LNP technology against Pfizer Inc., BioNTech SE and certain of their affiliates.“We, alongside our exclusive licensee Genevant, will continue to vigorously enforce our rights against infringers, including Pfizer and BioNTech,” said Arbutus Biopharma CEO Lindsay Androski.“Our March 2026 settlement with Moderna, and the July 2026 initial payment under that settlement, were critical milestones in establishing for the world what most of the scientific community already knew: Arbutus’ lipid nanoparticle technology inventions opened the doors to an entirely new world of therapeutic treatments using nucleic acids,” she added.<h2 class="st-heading-2">ABUS’ Q2 At A Glance</h2>During the second quarter, Arbutus Biopharma reported revenue of $1.01 million compared to an estimated $0.68 million as per Fiscal.ai data. The firm reported a loss of $0.03 per share compared to an estimated $0.02.Arbutus Biopharma ended the quarter with cash, cash equivalents, and investments in marketable securities of $92.6 million.<h2 class="st-heading-2">What Retail Thinks About ABUS</h2>On Stocktwits, retail sentiment continued to trend in the ‘extremely bullish’ territory amid high message volume.Stocktwits users expect the stock to rise to at least $6.5. It is currently trading close to $5.3, according to the pre-market rate.<stembedurl>https://stocktwits.com/Gugger/message/662506759</stembedurl><stembedurl>https://stocktwits.com/punktdot/message/662504166</stembedurl>The stock has gained nearly 33% in the last year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-issues-biggest-ever-recall-in-china-here-s-what-the-ev-maker-will-look-to-fix/cZYBMr6RJNn">Tesla Issues Biggest Ever Recall In China – Here’s What The EV Maker Will Look To Fix</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A researcher works in the clinical-stage biopharmaceutical company Xencors new laboratory in Pasadena.

Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.

Arbutus Biopharma Corp

Roivant Sciences Ltd

ProShares Ultra Russell2000

Vanguard Russell 2000 Growth ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

VTWG Vanguard Russell 2000 Growth ETF

Fundamentals

Latest VTWG News